- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Aliso Viejo Today
By the People, for the People
UBS Group Raises RxSight Price Target to $9
Analysts maintain 'neutral' rating on the medical technology company's stock
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
UBS Group analysts have raised their price target on shares of RxSight (NASDAQ:RXST) from $8.00 to $9.00, while maintaining a 'neutral' rating on the stock. RxSight is a medical technology company focused on developing and commercializing advanced intraocular lens (IOL) systems for cataract surgery and lens replacement procedures.
Why it matters
The updated price target from UBS Group reflects analysts' continued cautious outlook on RxSight's stock, despite the company's efforts to advance its flagship Light Adjustable Lens (LAL) technology. The LAL is designed to provide customized vision correction through non-invasive post-operative adjustments, which could enhance patient satisfaction.
The details
In a research note, UBS Group analysts cited RxSight's recent financial and operational performance as the basis for the price target increase, from $8.00 to $9.00 per share. However, the firm maintained its 'neutral' rating on the stock, suggesting that analysts see limited upside potential at this time. Other analysts have also issued mixed ratings and price targets for RxSight, with some seeing the company's technology as promising, while others remain cautious about its market positioning and competitive landscape.
- UBS Group issued the updated price target and rating on Thursday, February 26, 2026.
The players
RxSight
A medical technology company focused on developing and commercializing advanced intraocular lens (IOL) systems for cataract surgery and lens replacement procedures.
UBS Group
A global financial services firm that provides investment banking, asset management, and wealth management services.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The mixed analyst sentiment on RxSight's stock reflects the ongoing challenges and uncertainties facing the company as it seeks to establish its advanced IOL technology in the competitive medical device market. Investors will likely continue to closely monitor RxSight's progress in gaining market acceptance and regulatory approvals for its products.
